Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Use of Antiemetic Agents in Acute Gastroenteritis 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
Current Medical Research and Opinion, 09/30/09
Pratley RE et al. – Addition of alogliptin to pioglitazone therapy significantly improved glycemic control in patients with type 2 diabetes and was generally well tolerated. The study did not evaluate the effect of combination therapy on long–term clinical outcomes and safety.
Related Articles
Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia
Diabetes, Obesity and Metabolism, 11/12/09
Relevance Score: 94%
Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus
Journal of Clinical Endocrinology and Metabolism, 11/10/09
Relevance Score: 90%
Evidence for an association with type 2 diabetes mellitus at the PPARG locus in a South Indian population
Metabolism-Clinical and Experimental, 11/03/09
Relevance Score: 90%
Hepatic fat and inflammation in type 2 diabetes mellitus
Metabolism-Clinical and Experimental, 10/26/09
Relevance Score: 90%
Design of a family-based lifestyle intervention for youth with type 2 diabetes: the TODAY study
International Journal of Obesity, 10/16/09
Relevance Score: 90%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome
Diabetes Care, 11/25/09
Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified By National Cholesterol Education Program Risk Category
Metabolic Syndrome and Related Disorders, 11/25/09
Antiretroviral Therapy With Heart
American Journal of Therapeutics, 11/25/09
Today in Endocrinology...keeping you current
Receive free subspecialty "5-minute updates" via email
Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality
European Heart Journal, 11/24/09
Colesevelam HCl Improves Fasting Plasma Glucose and Lipid Levels in Patients with Prediabetes
Postgraduate Medicine, 11/24/09
Improvement in coronary endothelial function is independently associated with a slowed progression of coronary artery calcification in type 2 diabetes mellitus
European Heart Journal, 11/24/09
Article Search
Sponsor


See Latest Articles


